
M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 17-25, AIQGNVTSI
Description
About M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 17-25, AIQGNVTSI
The M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target Peptide (IEDB: 2058) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The 6 kDa early secretory antigenic target Peptide, H-AIQGNVTSI-OH (Uniprot: P9WNK7 aa: 17-25) from JPT is produced under strict quality control and quality management.
M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 17-25, AIQGNVTSI - Specifications
- Peptide sequence: H-AIQGNVTSI-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Tuberculosis
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 17-25, AIQGNVTSI
References:
Read References with JPT’s Antigen Peptides
M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 17-25, AIQGNVTSI has been described in:
Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis., Proc Natl Acad Sci U S A, 1998 (PMID: 9419365)
Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection., J Immunol, 2005 (PMID: 15699149)
The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1., J Immunol, 2000 (PMID: 11120837)
Documentation
Documentation for M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 17-25, AIQGNVTSI
Properties
Properties of M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 17-25, AIQGNVTSI
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Tuberculosis |
Layout: | Freeze-dried in glass vial |
Organism: | M. tuberculosis |
Protein Name: | 6 kDa early secretory antigenic target |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to M. tuberculosis (strain ATCC 25618 / H37Rv) 6 kDa early secretory antigenic target 17-25, AIQGNVTSI
Information | Values |
---|---|
Sequence: | H-AIQGNVTSI-OH |
Specifications: | 9mer peptide as TFA salt |